Bipolar Disorders in Saudi Arabia: What Do We Know So Far?

被引:0
|
作者
Almadani, Ahmad H. [1 ,2 ]
Alhadi, Ahmad N. [1 ,2 ,3 ]
Aldawood, Buthainah D. [4 ]
Aleissa, Mariam M. [5 ,6 ]
Alosaimi, Fahad D. [1 ,2 ]
机构
[1] King Saud Univ, Coll Med, Dept Psychiat, Riyadh, Saudi Arabia
[2] King Saud Univ, King Saud Univ Med City, Dept Psychiat, Riyadh, Saudi Arabia
[3] King Saud Univ, Coll Med, SABIC Psychol Hlth Res & Applicat Chair, Riyadh, Saudi Arabia
[4] Princess Nourah bint Abdulrahman Univ, Coll Hlth & Rehabil Sci, Dept Clin Psychol, Riyadh, Saudi Arabia
[5] Publ Hlth Lab, Dept Mol Genet, Publ Hlth Author, Riyadh, Saudi Arabia
[6] Alfaisal Univ, Med Sch, Riyadh, Saudi Arabia
关键词
Bipolar disorders; clinical manifestations; epidemiology; etiology; psychotropic medications; Saudi Arabia; OUTPATIENT PSYCHIATRIC SETTINGS; PREVALENCE; PATTERNS; INPATIENT; DIAGNOSES; STIGMA;
D O I
10.4103/sjmms.sjmms_306_24
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bipolar disorders (BP) are prevalent neuropsychiatric illnesses affecting 1%-5% of the global population and about 3% of the Saudi population. They are associated with significant comorbidities and negative consequences. Despite being common mental health conditions in Saudi Arabia, stigma persists, with weak character, supernatural beliefs, and weak faith considered as causes. In addition, Saudi patients with BP have been reported to seek help from non-psychiatric healthcare professionals and faith healers. More data are required on BP from Saudi Arabia, including the genetic aspects and their treatment approaches. This narrative review paper explores the epidemiology and clinical manifestations, etiology and biological mechanisms, public knowledge and awareness of the illnesses, and treatment of BP in Saudi Arabia.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 50 条
  • [21] What we know so far
    Gazzard, B
    AIDS, 1996, 10 : S3 - S7
  • [22] Lisfranc Sports Injuries: What Do We Know So Far?
    Maduka, Godsfavour C.
    Maduka, Divinegrace C.
    Yusuf, Naeem
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [23] What do we know about DNA mechanics so far?
    Aggarwal, Abhishek
    Naskar, Supriyo
    Sahoo, Anil Kumar
    Mogurampelly, Santosh
    Garai, Ashok
    Maiti, Prabal K.
    CURRENT OPINION IN STRUCTURAL BIOLOGY, 2020, 64 : 42 - 50
  • [24] Leishmaniasis in transplant patients: what do we know so far?
    Monge-Maillo, Begona
    Lopez-Velez, Rogelio
    CURRENT OPINION IN INFECTIOUS DISEASES, 2024, 37 (05) : 342 - 348
  • [25] Electronic Cigarettes and Asthma: What Do We Know So Far?
    Kotoulas, Serafeim-Chrysovalantis
    Katsaounou, Paraskevi
    Riha, Renata
    Grigoriou, Ioanna
    Papakosta, Despoina
    Spyratos, Dionysios
    Porpodis, Konstantinos
    Domvri, Kalliopi
    Pataka, Athanasia
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (08):
  • [26] Securitisation and banking risk: what do we know so far?
    Kara, Alper
    Ozkan, Aydin
    Altunbas, Yener
    REVIEW OF BEHAVIORAL FINANCE, 2016, 8 (01) : 2 - 16
  • [27] Naming: What Do We Know So Far? A Systematic Review
    Maithri Sivaraman
    Dermot Barnes-Holmes
    Perspectives on Behavior Science, 2023, 46 : 585 - 615
  • [28] Rehabilitation Intensity in Ontario: What Do We Know So Far?
    Elizabeth, Linkewich
    Ryan, Metcalfe
    Ruth, Hall
    Sylvia, Quant
    INTERNATIONAL JOURNAL OF STROKE, 2017, 12 : 59 - 60
  • [29] Chagas Disease Chemotherapy: What Do We Know So Far?
    Zuma, Aline A.
    de Souza, Wanderley
    CURRENT PHARMACEUTICAL DESIGN, 2021, 27 (38) : 3963 - 3995
  • [30] Selective IgM deficiency: what do we know so far?
    Batista, Caroline Hamati
    Smanio, Maria Carolina
    Kokron, Cristina
    Agondi, Rosana
    Ferraroni, Natasha
    Roxo, Persio, Jr.
    Ferriani, Mariana
    Chong, Herberto
    Rosario Filho, Nelson
    Kamoi, Tsukiyo
    Di Gesu, Regina
    Goudouris, Ekaterini
    Aranda, Carolina
    Mansour, Eli
    Resende, Leticia
    Grumach, Anete
    JOURNAL OF CLINICAL IMMUNOLOGY, 2022, 42 (SUPPL 1) : S87 - S87